3a diagnostics GmbH

3a-diagnostics GmbH, based in Frickenhausen, Germany, is a biotechnology company specializing in the development of innovative diagnostic solutions. The company is particularly known for its advances in point-of-care diagnostics, which enable the rapid and reliable detection of diseases directly at the point of sample collection. In 2021, 3a-diagnostics was acquired by the Canadian XPhyto Therapeutics Corp. to expand its expertise in biotechnology and diagnostics. The company focused on developing biosensing platforms and diagnostic tests that are easy to use and cost-effective. Core technologies include: Biosensors: Highly sensitive and precise sensors for the detection of infectious agents, Rapid tests: diagnostic tests for point-of-care applications that can be performed without the need for costly laboratory infrastructure, Innovative materials: microbial detection systems for human and veterinary medicine.

Further information on the websites of BIOPRO Baden-Württemberg: